Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence.
L'Huillier AG, Pagano S, Baggio S, Meyer B, Andrey DO, Nehme M, Guessous I, Eberhardt CS, Huttner A, Posfay-Barbe KM, Yerly S, Siegrist CA, Kaiser L, Vuilleumier N. L'Huillier AG, et al. Among authors: nehme m. Eur J Clin Invest. 2022 Oct;52(10):e13818. doi: 10.1111/eci.13818. Epub 2022 Jun 2. Eur J Clin Invest. 2022. PMID: 35598178 Free PMC article.
[Telemedicine at the heart of management of the COVID-19 crisis].
Mazouri-Karker S, Percheron Vendeuvre L, Sandoval J, Regard S, Braillard O, Guessous I, Nehme M. Mazouri-Karker S, et al. Among authors: nehme m. Rev Med Suisse. 2020 Sep 16;16(706):1699-1702. Rev Med Suisse. 2020. PMID: 32936553 French.
Adultes en situation de handicap : rien sur nous sans nous.
Héritier Barras AC, Nehme M, Haller DM, Guessous I. Héritier Barras AC, et al. Among authors: nehme m. Rev Med Suisse. 2020 Sep 30;16(708):1783-1784. Rev Med Suisse. 2020. PMID: 32997446 French. No abstract available.
Novel outpatient management of mild to moderate COVID-19 spares hospital capacity and safeguards patient outcome: The Geneva PneumoCoV-Ambu study.
Chevallier Lugon C, Smit M, Salamun J, Abderrahmane M, Braillard O, Nehme M, Jacquerioz Bausch F, Guessous I, Spechbach H. Chevallier Lugon C, et al. Among authors: nehme m. PLoS One. 2021 Mar 4;16(3):e0247774. doi: 10.1371/journal.pone.0247774. eCollection 2021. PLoS One. 2021. PMID: 33662012 Free PMC article.
Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study.
Leidi A, Koegler F, Dumont R, Dubos R, Zaballa ME, Piumatti G, Coen M, Berner A, Darbellay Farhoumand P, Vetter P, Vuilleumier N, Kaiser L, Courvoisier D, Azman AS, Guessous I, Stringhini S; SEROCoV-POP study group. Leidi A, et al. Clin Infect Dis. 2022 Mar 1;74(4):622-629. doi: 10.1093/cid/ciab495. Clin Infect Dis. 2022. PMID: 34043763 Free PMC article.
Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland.
Stringhini S, Zaballa ME, Pullen N, de Mestral C, Perez-Saez J, Dumont R, Picazio A, Pennacchio F, Dibner Y, Yerly S, Baysson H, Vuilleumier N, Balavoine JF, Bachmann D, Trono D, Pittet D, Chappuis F, Kherad O, Kaiser L, Azman AS; SEROCoV-WORK + Study Group; Guessous I. Stringhini S, et al. Nat Commun. 2021 Jun 8;12(1):3455. doi: 10.1038/s41467-021-23796-4. Nat Commun. 2021. PMID: 34103517 Free PMC article.
74 results